CJC-1295 no DAC

What Is CJC‑1295 no DAC?

CJC‑1295 no DAC is a truncated synthetic peptide analog of growth hormone–releasing hormone (GHRH), engineered without the drug affinity complex (DAC) modification. This design confers a shorter half‑life compared to CJC‑1295 with DAC, allowing for pulsatile GH release more closely mimicking physiological secretion patterns.

Mechanism of Action

CJC‑1295 no DAC binds to GHRH receptors on anterior pituitary somatotrophs, stimulating cyclic AMP signaling and calcium influx. This receptor activation promotes endogenous growth hormone release, which subsequently elevates circulating insulin‑like growth factor‑1 (IGF‑1) levels. The absence of DAC modification results in rapid clearance, producing a shorter duration of action but preserving the natural episodic rhythm of GH secretion. This pharmacological profile is often studied for its potential to enhance recovery, lean tissue growth, and metabolic regulation without prolonged receptor engagement.

Research & Clinical Data

CJC‑1295 no DAC remains investigational, with limited human clinical trial data. Preclinical studies and anecdotal reports suggest benefits in tissue repair, lipid metabolism, and anabolic recovery. Comparative analyses highlight differences in pharmacokinetics between DAC‑modified and non‑DAC formulations, with the latter favored in contexts requiring shorter GH stimulation windows. Regulatory approval for therapeutic use has not been established.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: GHRH analog | Modification: No DAC | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, non‑approved